Clene Inc (CLNN)

$8.34 +0.19 (2.39%)
Market Cap 82.02M
Revenue (ttm) 340,000.00
Net Income (ttm) -39.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11,588.24%
Debt to Equity Ratio -0.54
Volume 66,400
Avg Vol 124,728
Day's Range N/A - N/A
Shares Out 10.07M
Stochastic %K 39%
Beta 0.62
Analysts Strong Sell
Price Target $30.43

Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; comp...

Industry: Packaged Foods
Sector: Consumer Defensive
Phone: 801 676 9695
Website: clene.com
Address:
6550 South Millrock Drive, Suite G50, Salt Lake City, United States
neuroinvestor3
neuroinvestor3 Oct. 25 at 11:46 AM
$CLNN from chatGPT - “I assess the probability of accelerated approval next year for CNM-Au8 in ALS at a moderate but not high level — perhaps in the 30-50% range, contingent on many moving parts.“
1 · Reply
GJ_Rockabilt
GJ_Rockabilt Oct. 25 at 5:48 AM
$CLNN December? I'm ba patient man, but let's talk about November, anyways. Now, then, according to GOOGLE: "By acting as a surrogate endpoint for clinical benefit, NfL data can speed up the drug development process. For rare diseases (like ALS) with limited treatment options, regulatory agencies like the FDA may approve a drug based on strong NfL data alone, with confirmatory trials to follow."
0 · Reply
fibonacci1170
fibonacci1170 Oct. 24 at 8:58 PM
$CLNN 91% reduction in "time to death" after 12 months of therapy. Even the sleazy FDA can't deny accelerated approval, surely. If they do deny, ALS patients should sue the FDA in court and demand an FBI probe. Unfortunately, these government agencies are only good at probing some small-fish casinos that nobody cares about instead of exposing the FDA-pharma mafia that is slaughtering millions of patients by denying them treatment.
0 · Reply
Mulhollandr
Mulhollandr Oct. 24 at 5:32 PM
$CLNN just my opinion but I think someone is grabbigg by shares quietly trying not to spike the price. Wonder when they will be done loading. 🤔
1 · Reply
ransoms2121212
ransoms2121212 Oct. 24 at 3:43 PM
$CLNN volume off to a strong start
1 · Reply
Mulhollandr
Mulhollandr Oct. 23 at 9:47 PM
$CLNN FDA minutes or EAP data…which do we get first? If they are still thinking nda submission could happen this year…data is coming soon? I think shutdown will slow down minutes from type C.
3 · Reply
Scoops1212
Scoops1212 Oct. 23 at 8:12 PM
$CLNN
0 · Reply
Chris150
Chris150 Oct. 23 at 7:31 PM
$CLNN https://www.youtube.com/watch?v=DIo6uZV8sog
0 · Reply
Acx21
Acx21 Oct. 23 at 7:25 PM
$CLNN I was listening to the conference and to make it short: The NfL data is not analysed yet or not available to CLNN by now. Still, Rob seemed to be very confident about a succesful NDA in december if the NfL data is concordant to previous results. The next FDA meeting is scheduled for december and so is the planned timeline for the NDA filling
0 · Reply
LXP
LXP Oct. 23 at 7:24 PM
$CLNN whelp, thoughts? Seems like a little more waiting. Nfl data likely in November. Fda meeting in December. NDA if all goes well, by EOY
0 · Reply
Latest News on CLNN
Clene to Present at the Emerging Growth Conference

Oct 20, 2025, 8:30 AM EDT - 5 days ago

Clene to Present at the Emerging Growth Conference

Clene to Participate in a Panel Discussion at the Maxim Growth Summit

Oct 15, 2025, 8:30 AM EDT - 10 days ago

Clene to Participate in a Panel Discussion at the Maxim Growth Summit

Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients

Sep 25, 2025, 8:00 AM EDT - 4 weeks ago

Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease

Sep 4, 2025, 8:30 AM EDT - 7 weeks ago

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease

Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 7 weeks ago

Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Aug 14, 2025, 8:38 AM EDT - 2 months ago

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Clene to Present at the Canaccord 45th Annual Growth Conference

Aug 5, 2025, 8:30 AM EDT - 2 months ago

Clene to Present at the Canaccord 45th Annual Growth Conference

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Jun 30, 2025, 8:00 AM EDT - 4 months ago

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

Jun 9, 2025, 9:00 AM EDT - 4 months ago

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

May 7, 2025, 8:00 AM EDT - 6 months ago

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Clene to Present at the Jones Healthcare and Technology Innovation Conference

Apr 1, 2025, 8:30 AM EDT - 7 months ago

Clene to Present at the Jones Healthcare and Technology Innovation Conference

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Mar 24, 2025, 8:00 AM EDT - 7 months ago

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Mar 12, 2025, 8:00 AM EDT - 8 months ago

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Clene to Present at the 37TH Annual Roth Conference

Mar 6, 2025, 8:30 AM EST - 8 months ago

Clene to Present at the 37TH Annual Roth Conference

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Feb 27, 2025, 9:15 AM EST - 8 months ago

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction

Feb 25, 2025, 8:00 AM EST - 8 months ago

Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Dec 10, 2024, 8:30 AM EST - 11 months ago

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Aug 8, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Aug 7, 2024, 8:23 AM EDT - 1 year ago

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Jul 11, 2024, 9:00 AM EDT - 1 year ago

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Clene Announces 1-for-20 Reverse Stock Split

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Clene Announces 1-for-20 Reverse Stock Split

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Jun 21, 2024, 7:09 AM EDT - 1 year ago

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

Jun 18, 2024, 7:00 AM EDT - 1 year ago

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

May 28, 2024, 7:30 AM EDT - 1 year ago

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

Clene to Present at Upcoming May Conferences

May 14, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at Upcoming May Conferences

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

May 8, 2024, 8:00 AM EDT - 1 year ago

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

Apr 16, 2024, 4:01 PM EDT - 1 year ago

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Feb 29, 2024, 8:00 AM EST - 1 year ago

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Clene says FDA finds ALS drug data not enough for accelerated nod

Dec 21, 2023, 11:25 AM EST - 2 years ago

Clene says FDA finds ALS drug data not enough for accelerated nod

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Dec 21, 2023, 7:00 AM EST - 2 years ago

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Clene Provides Update on ALS Clinical Development Meeting With FDA

Dec 21, 2023, 7:00 AM EST - 2 years ago

Clene Provides Update on ALS Clinical Development Meeting With FDA

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Dec 14, 2023, 8:36 AM EST - 2 years ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Nov 7, 2023, 8:00 AM EST - 2 years ago

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Oct 5, 2023, 10:00 AM EDT - 2 years ago

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Sep 25, 2023, 4:00 PM EDT - 2 years ago

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

Sep 25, 2023, 7:00 AM EDT - 2 years ago

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

Clene to Present at Upcoming September Conferences

Aug 30, 2023, 8:20 AM EDT - 2 years ago

Clene to Present at Upcoming September Conferences

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

Aug 2, 2023, 7:00 AM EDT - 2 years ago

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET's eClinicalMedicine

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET's eClinicalMedicine

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

Jun 21, 2023, 9:20 AM EDT - 2 years ago

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

Clene Announces Pricing of $40 Million Public Offering

Jun 16, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Pricing of $40 Million Public Offering

neuroinvestor3
neuroinvestor3 Oct. 25 at 11:46 AM
$CLNN from chatGPT - “I assess the probability of accelerated approval next year for CNM-Au8 in ALS at a moderate but not high level — perhaps in the 30-50% range, contingent on many moving parts.“
1 · Reply
GJ_Rockabilt
GJ_Rockabilt Oct. 25 at 5:48 AM
$CLNN December? I'm ba patient man, but let's talk about November, anyways. Now, then, according to GOOGLE: "By acting as a surrogate endpoint for clinical benefit, NfL data can speed up the drug development process. For rare diseases (like ALS) with limited treatment options, regulatory agencies like the FDA may approve a drug based on strong NfL data alone, with confirmatory trials to follow."
0 · Reply
fibonacci1170
fibonacci1170 Oct. 24 at 8:58 PM
$CLNN 91% reduction in "time to death" after 12 months of therapy. Even the sleazy FDA can't deny accelerated approval, surely. If they do deny, ALS patients should sue the FDA in court and demand an FBI probe. Unfortunately, these government agencies are only good at probing some small-fish casinos that nobody cares about instead of exposing the FDA-pharma mafia that is slaughtering millions of patients by denying them treatment.
0 · Reply
Mulhollandr
Mulhollandr Oct. 24 at 5:32 PM
$CLNN just my opinion but I think someone is grabbigg by shares quietly trying not to spike the price. Wonder when they will be done loading. 🤔
1 · Reply
ransoms2121212
ransoms2121212 Oct. 24 at 3:43 PM
$CLNN volume off to a strong start
1 · Reply
Mulhollandr
Mulhollandr Oct. 23 at 9:47 PM
$CLNN FDA minutes or EAP data…which do we get first? If they are still thinking nda submission could happen this year…data is coming soon? I think shutdown will slow down minutes from type C.
3 · Reply
Scoops1212
Scoops1212 Oct. 23 at 8:12 PM
$CLNN
0 · Reply
Chris150
Chris150 Oct. 23 at 7:31 PM
$CLNN https://www.youtube.com/watch?v=DIo6uZV8sog
0 · Reply
Acx21
Acx21 Oct. 23 at 7:25 PM
$CLNN I was listening to the conference and to make it short: The NfL data is not analysed yet or not available to CLNN by now. Still, Rob seemed to be very confident about a succesful NDA in december if the NfL data is concordant to previous results. The next FDA meeting is scheduled for december and so is the planned timeline for the NDA filling
0 · Reply
LXP
LXP Oct. 23 at 7:24 PM
$CLNN whelp, thoughts? Seems like a little more waiting. Nfl data likely in November. Fda meeting in December. NDA if all goes well, by EOY
0 · Reply
Takeover24
Takeover24 Oct. 23 at 7:23 PM
$CLNN 10 minute update over. Nothing new. Says they dont yet have the NFL data yet which does not make sense based other prior timelines. Did not address whether the FDA meeting on the survival data actually happened end of Q3 or not. That said, still talked about a meeting with the FDA in Dec and the possibility of filing NDA at end of year. Sounded confident. Also talked about cash position being sufficient to get company through these key inflection points (into Q2 of next year).
1 · Reply
LXP
LXP Oct. 23 at 6:42 PM
$CLNN just hoping for some clues where they are at in the process.
0 · Reply
Takeover24
Takeover24 Oct. 23 at 5:11 PM
$CLNN The market is exploding with anticipation about what Rob is going to say at the conference in a few hours 😴
3 · Reply
Mulhollandr
Mulhollandr Oct. 23 at 2:49 PM
$CLNN roughly 70% of the volume today appears to be dark pool. I find this strange considering the volume is so low. 🤔
1 · Reply
neuroinvestor3
neuroinvestor3 Oct. 23 at 2:09 PM
$CLNN https://www.tipranks.com/news/ratings/clenes-cnm-au8-a-promising-game-changer-in-als-treatment-with-buy-rating-from-justin-walsh-ratings
1 · Reply
neuroinvestor3
neuroinvestor3 Oct. 23 at 2:09 PM
$CLNN I don't think we'll get any PR's from Clene related to the FDA until the guv reopens.
1 · Reply
mrpsny
mrpsny Oct. 23 at 12:49 PM
$CLNN wouldn't mind scooping up some more. Issue is, I'll be averaging up. Soo... stay down!!
0 · Reply
Mulhollandr
Mulhollandr Oct. 23 at 11:03 AM
$CLNN c’mon Rob!
0 · Reply
NoFearHere
NoFearHere Oct. 22 at 8:56 PM
$CLNN going back to $6.70 the 50 dma
1 · Reply
Bobfree
Bobfree Oct. 22 at 8:12 PM
$CLNN A no news Wednesday. Shocking. Not that I'm feeling impatient
0 · Reply
neuroinvestor3
neuroinvestor3 Oct. 22 at 5:52 PM
$CLNN down 9% seems extreme on no news.....
1 · Reply
ransoms2121212
ransoms2121212 Oct. 22 at 5:49 PM
$CLNN link for the KOL call on November 4th for anyone else interested—this link comes from the below screenshot. List Justin Walsh as Jones contact @Mulhollandr @Chris150 @neuroinvestor3 @Scoops1212 @fibonacci1170 https://zoom.us/webinar/register/WN_TvHaommTSsuizqBpUauRjg#/registration
1 · Reply